Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer

Yu-Yang Bi,Qiu Chen,Ming-Yuan Yang,Lei Xing,Hu-Lin Jiang

DOI: https://doi.org/10.1038/s41467-024-47080-3

IF: 16.6

2024-03-29

Nature Communications

Abstract:Abstract Non-small cell lung cancer (NSCLC) shows high drug resistance and leads to low survival due to the high level of mutated Tumor Protein p53 ( TP53 ). Cisplatin is a first-line treatment option for NSCLC, and the p53 mutation is a major factor in chemoresistance. We demonstrate that cisplatin chemotherapy increases the risk of TP53 mutations, further contributing to cisplatin resistance. Encouragingly, we find that the combination of cisplatin and fluvastatin can alleviate this problem. Therefore, we synthesize Fluplatin, a prodrug consisting of cisplatin and fluvastatin. Then, Fluplatin self-assembles and is further encapsulated with poly-(ethylene glycol)–phosphoethanolamine (PEG–PE), we obtain Fluplatin@PEG–PE nanoparticles (FP NPs). FP NPs can degrade mutant p53 (mutp53) and efficiently trigger endoplasmic reticulum stress (ERS). In this study, we show that FP NPs relieve the inhibition of cisplatin chemotherapy caused by mutp53, exhibiting highly effective tumor suppression and improving the poor NSCLC prognosis.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper attempts to address the major issues encountered in the treatment of non-small cell lung cancer (NSCLC), namely high drug resistance and low survival rates, which are largely caused by mutations in the tumor protein p53. Cisplatin, as the first-line treatment for NSCLC, often has its efficacy limited due to chemotherapy resistance induced by p53 mutations. Studies have found that cisplatin chemotherapy not only increases the risk of TP53 mutations but also further exacerbates cisplatin resistance. Therefore, the paper proposes the synthesis of a prodrug, Fluplatin, by combining cisplatin and fluvastatin, and self-assembling it into nanoparticles (FP NPs) to overcome the issues of chemotherapy resistance and tumor recurrence caused by mutant p53 (mutp53).

Specifically, FP NPs can degrade mutp53 and efficiently trigger endoplasmic reticulum stress (ERS), thereby alleviating the reduced therapeutic effect of cisplatin chemotherapy caused by mutp53 inhibition, demonstrating high tumor suppression efficacy and improving the poor prognosis of NSCLC patients. The paper validates the effectiveness of FP NPs through a series of experiments, including cytotoxicity tests, apoptosis analysis, and ROS level detection, proving that FP NPs have significantly better anti-tumor effects in different cell lines compared to cisplatin alone. Additionally, FP NPs can effectively activate ERS-related pro-apoptotic signaling pathways, a mechanism independent of the p53 pathway, thereby enhancing the therapeutic effect on cells expressing both mutp53 and wild-type p53 (wtp53).